

Sarepta Therapeutics Regains NASDAQ Compliance

July 27, 2012 9:13 AM ET

Jul 27, 2012 (Marketwire via COMTEX) --Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today that it received a letter from the listing qualifications department staff of The NASDAQ Stock Market LLC, stating that the Company has regained compliance with NASDAQ's minimum \$1.00 per share bid price requirement.

The letter received noted that for 10 consecutive business days, from July 12, 2012 to July 25, 2012, the closing bid price of the Company's common stock was \$1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5450(a)(1) and the matter is closed.

About Sarepta Therapeutics

Sarepta Therapeutics -- formerly AVI BioPharma -- is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNA-based science into transformational therapeutics for patients who face significant unmet medical needs. For more information, please visit us at www.sareptatherapeutics.com.

Sarepta Investor and Media Contact:
Erin Cox
425.354.5140
Email Contact